These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18008252)

  • 21. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients.
    Cavdar C; Sayan M; Sifil A; Artuk C; Yilmaz N; Bahar H; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):71-6. PubMed ID: 12745749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum antibodies against circulating influenza strains among vaccinated and unvaccinated general practitioners during two consecutive years (2002-2003).
    Michiels B; Philips H; Coenen S; Denekens J; Van Royen P
    Vaccine; 2006 Apr; 24(16):3145-52. PubMed ID: 16490288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response.
    Szyszko E; Brokstad K; Cox RJ; Hovden AO; Madhun A; Haaheim LR
    Scand J Immunol; 2006 Nov; 64(5):467-75. PubMed ID: 17032238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice.
    Hauge S; Madhun AS; Cox RJ; Brokstad KA; Haaheim LR
    Scand J Immunol; 2007 Jan; 65(1):14-21. PubMed ID: 17212762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody responses after dose-sparing intradermal influenza vaccination.
    Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
    Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.
    Xie H; Liu TM; Lu X; Wu Z; Belser JA; Katz JM; Tumpey TM; Ye Z
    J Infect Dis; 2009 Dec; 200(12):1874-83. PubMed ID: 19909080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
    J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice.
    Matsui M; Kohyama S; Suda T; Yokoyama S; Mori M; Kobayashi A; Taneichi M; Uchida T
    Biochem Biophys Res Commun; 2010 Jan; 391(3):1494-9. PubMed ID: 20060099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease.
    Mamula P; Markowitz JE; Piccoli DA; Klimov A; Cohen L; Baldassano RN
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):851-6. PubMed ID: 17544875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus.
    Holvast A; van Assen S; de Haan A; Huckriede A; Benne CA; Westra J; Palache A; Wilschut J; Kallenberg CG; Bijl M
    Arthritis Rheum; 2009 Aug; 60(8):2438-47. PubMed ID: 19644961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports.
    Pedersen G; Halstensen A; Sjursen H; Naess A; Kristoffersen EK; Cox RJ
    Scand J Immunol; 2011 Aug; 74(2):210-8. PubMed ID: 21438900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation.
    Avetisyan G; Aschan J; Hassan M; Ljungman P
    Transplantation; 2008 Jul; 86(2):257-63. PubMed ID: 18645488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.